FACULTYOPINIONS . COM {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Facultyopinions.com Make Money
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Hosting Providers

We began analyzing https://archive.connect.h1.co/article/735413378/, but it redirected us to https://archive.connect.h1.co/article/735413378/. The analysis below is for the second page.

Title[redir]:
Inhibition of USP2 eliminates canc ... | Article | H1 Connect
Description:
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that harbors enriched cancer stem cell (CSC) populations in tumors. Co

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is facultyopinions.com built with?

Custom-built

No common CMS systems were detected on Facultyopinions.com, but we identified it was custom coded using Next.js (JavaScript).

Traffic Estimate {📈}

What is the average monthly size of facultyopinions.com audience?

🚗 Small Traffic: 1k - 5k visitors per month

Based on our best estimate, this website will receive around 1,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Facultyopinions.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Facultyopinions.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, recommendation, finding, latest, cell, stem, cells, molecular, transition, breast, faculty, biology, therapeutics, control, drug, epithelialmesenchymal, nov, good, jean, clairambault, genomes, epigenomes, growth, division, gene, expression, developmental, mechanisms, target, sep, metastasis, mammary, inhibition, show, jun, epithelial, mesenchymal, review, regeneration, apr, signaling, avri, benzeev, jan, teaching, emt, stemness, ron, prywes, technical,

Topics {✒️}

undergo epithelial-mesenchymal transition epithelial-mesenchymal transition cancer stem cells cancer drug resistance cancer therapeutics breast cancer cells stem cell properties finding emerging mechanisms breast cancer metastasis drug target 1 mesenchymal transition mammary gland development induces mammary tumors finding protein kinase finding six1 expands central signaling node breast cancer enhances tnbc responsiveness transcriptionally repressing snail2 low cohesion characteristics gene expression bitopic mtor inhibition molecular regulation gastric cancer links epithelial jean clairambault therapeutic target faculty review negative regulator finding loss faculty opinions h1 company tumor stemness archived inhibition authors show activation doctors search 1038/s41419-019-1512-6 pmid sheds light important factors seed metastases article referenced shensi shen modulating mirnas chang cj tam wl finding wilson mm liu yj mccoy el

Schema {🗺️}

ScholarlyArticle:
      context:https://schema.org
      headline:Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
      abstract:Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that harbors enriched cancer stem cell (CSC) populations in tumors. Conventional chemotherapy is a standard treatment for TNBC, but it spares the CSC populations, which cause tumor recurrence and progression. Therefore, identification of the core molecular pathway that controls CSC activity and expansion is essential for developing effective therapeutics for TNBC. In this study, we identify that USP2 deubiquitinating enzyme is upregulated in CSCs and is a novel regulator of CSCs. Genetic and pharmacological targeting of USP2 substantially inhibits the self-renewal, expansion and chemoresistance of CSCs. We show that USP2 maintains the CSC population by activating self-renewing factor Bmi1 and epithelial-mesenchymal transition through Twist upregulation. Mechanistically, USP2 promotes Twist stabilization by removing β-TrCP-mediated ubiquitination of Twist. Animal studies indicate that pharmacological inhibition of USP2 suppresses tumor progression and sensitizes tumor responses to chemotherapy in TNBC. Furthermore, the histological analyses reveal a positive correlation between USP2 upregulation and lymph node metastasis. Our findings together demonstrate a previously unrecognized role of USP2 in mediating Twist activation and CSC enrichment, suggesting that targeting USP2 is a novel therapeutic strategy to tackle TNBC.
      hasPart:
         type:WebPageElement
         isAccessibleForFree:
         cssSelector:.paywalled-content
      isAccessibleForFree:
      mainEntityOfPage:
         type:WebPage
         id:https://connect.h1.co/article/735413378
WebPage:
      id:https://connect.h1.co/article/735413378

Social Networks {👍}(2)

External Links {🔗}(41)

Analytics and Tracking {📊}

Google Analytics
Google Tag Manager

Emails and Hosting {✉️}

Mail Servers:

aspmx.l.google.com
alt1.aspmx.l.google.com
alt2.aspmx.l.google.com
alt3.aspmx.l.google.com
alt4.aspmx.l.google.com

Name Servers:

ns-1466.awsdns-55.org
ns-15.awsdns-01.com
ns-1815.awsdns-34.co.uk
ns-887.awsdns-46.net

4.77s.